ArticleProceedings of the National Academy of Sciences of the United States of America2026
Glycosylation of GETV E2 promotes pathogenesis in animal models.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A conserved E1 stem motif functions as a virulence switch in the emerging Getah virus.Virulence · 2026Article
- Potential threats of porcine Getah virus outbreaks and its specific antagonism of host antiviral response through proteasome-dependent degradation of P46 by nsP2.PLoS pathogens · 2026Article
- Development and validation of an E2 based indirect ELISA for serological detection of porcine Getah virus.Veterinary research communications · 2026Article
- Re-Emergence and Characterization of a Highly Pathogenic Getah Virus on a Pig Farm in Guangdong Province, China.Microorganisms · 2026Article
- Defining the impact of Getah virus envelope protein glycosylation site mutations on viral replication, host adaptation, virulence, and immune evasion.PLoS pathogens · 2026Article
- Therapeutic Potential of Somatostatin and Its Analogues in Alzheimer's Disease: From Molecular Mechanisms to Preclinical Studies.Molecular neurobiology · 2026Review
- Highly Virulent Getah Virus Subgroup GIII-c Emerging in Pigs in China.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Getah virus (GETV) is a mosquito-borne alphavirus. It has posed a threat to various livestock and humans during decades of evolution and spread. However, the viral determinants and mechanisms underlying enhanced virulence remain largely unknown. In this study, we identified E2-N262 glycosylation in GETV as an evolutionary adaptation that promotes receptor binding, innate immune evasion, and virulence. Using reverse genetics technology, we generated recombinant GETV strains-rSD2206 WT and the N262D substitution. In vitro, rSD2206 WT formed larger plaques and replicated more efficiently across multiple cell lines. Despite exhibiting enhanced pathogenicity, higher replication efficiency, and a weaker induction of host antiviral responses compared to the N262D virus in both mouse and suckling pig models, the rSD2206 WT virus retained immunogenicity. Mechanistically, we found that rSD2206 WT increased virion attachment and entry into host cells by enhancing binding affinity to both HS (a GETV attachment factor) and LDLR (a GETV receptor). In addition, the rSD2206 WT strain can evade the host's antiviral response by interrupting the activation of interferon regulatory factor 3. Structural analysis revealed a significant reduction in binding free energy for rSD2206 WT. This reduction resulted in conformational changes within the E2 protein, which in turn enhanced its stability and subsequently strengthening its receptor-binding capacity. Ultimately, compared to N262D, rSD2206 WT exhibited increased replication in cells overexpressing LDLR, but significantly reduced replication in LDLR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.